| Active substance |
Raloxifene HCL |
| Also known as |
Raloxifene hydrochloride |
| Blood pressure |
Typically has no significant effect on blood pressure |
| Chemical name |
[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride |
| Dosage (medical) |
Commonly prescribed as 60 mg per day |
| Dosage (sports) |
Not typically used in sports for performance enhancement |
| Effects |
Reduces the risk of osteoporosis, decreases total and LDL cholesterol |
| Formula |
C28H27NO4SВ·HCl |
| Half-life |
Approximately 27.7 hours |
| Hepatotoxicity |
Low risk |
| Lab Test |
Not specific, general liver function tests may be monitored |
| Main action |
Estrogen receptor modulator |
| Side effects |
Hot flashes, leg cramps, increased risk of venous thromboembolism, stroke |
| Storage conditions |
Store at room temperature, protect from moisture and heat |
| Substance class |
Selective Estrogen Receptor Modulator (SERM) |
| Trade name |
Evista |
| Use in sports |
None, as it is not known for performance enhancement |
| Water Retention |
None |
| Active ingredient, mg |
30 |
| Release form |
Tablets |
| 1 Pill, mg |
30 |
| Manufacturer |
Driada Medical |
| Packing |
Packaging (50 tablets) |
